Journal Home
Search for

Articles in Press

Return to articles in press list

Concordance for IBD among twins compared to ordinary siblings — A Norwegian population-based study

May-Bente BengtsonaCorresponding Author Informationemail address, Geir Aamodtbemail address, Morten H. Vatncdemail address, Jennifer R. Harrisbemail address

Received 20 October 2009; received in revised form 10 December 2009; accepted 10 December 2009. published online 04 January 2010.
Corrected Proof

Abstract 

Aims

Comparing the risk to develop concordant disease among twins with inflammatory bowel disease (IBD) to ordinary siblings. Moreover, clinical characteristics of IBD and the association between perinatal factors and IBD, were evaluated.

Methods

Patients with IBD, enrolled from an incidence study between 1990 and 1994, and the twins were identified from the Norwegian national birth registry, which was established in 1967.

Results

Eight monozygotic and 16 dizygotic pairs, in which at least one twin reported a positive history of IBD were compared to 84 patients with Crohn's disease (CD) and 87 patients with ulcerative colitis (UC) from the incidence study. The relative risks for concordant disease in monozygotic pairs were estimated to 95.4 (95% CI: 76.3, 114.6) and 49.5 (95% CI: 35.7, 63.3) for CD and UC, respectively. The corresponding risks in dizygotic pairs were 42.4 (95% CI: 29.6, 55.2) and 0.0. Among ordinary siblings of CD and UC the risks for concordance were 22.7 (95% CI: 13.3, 32.1) and 4.6 (95% CI: 0.4, 8.7), respectively.

Stricturing disease was significantly higher in twins with CD compared to incidental cases. The first-born twin in pairs discordant for disease, 12 out of 19 (63.2%), tended to be affected by IBD (p=0.10).

Conclusion

Genetic factors influence the development of IBD and fibrostenotic disease in CD. The increased risk for concordant disease among dizygotic twins compared to ordinary siblings, at least in CD, might underscore the importance of shared environment in utero or in childhood.

a Medical Department, Tonsberg County Hospital, Tonsberg, Norway

b The Norwegian Institute of Public Health, Oslo, Norway

c EpiGen-Institute, Faculty Division Akershus University Hospital, University of Oslo, Norway

d Medical Clinic, Rikshospitalet, Oslo University Hospital, Oslo, Norway

Corresponding Author InformationCorresponding author. Lokesvei 10, Åsgårdstand 3179, Norway. Tel.: +47 93236365, +47 33 049241 (home); fax: +47 33 343949.

PII: S1873-9946(09)00151-2

doi:10.1016/j.crohns.2009.12.008